COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

The Vascutek AnacondaTM Stent Graft System Phase II IDE Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00612924
Recruitment Status : Completed
First Posted : February 12, 2008
Results First Posted : March 9, 2016
Last Update Posted : October 16, 2017
Vascutek Ltd.
Information provided by (Responsible Party):
Terumo CVS

Tracking Information
First Submitted Date  ICMJE January 22, 2008
First Posted Date  ICMJE February 12, 2008
Results First Submitted Date  ICMJE February 10, 2016
Results First Posted Date  ICMJE March 9, 2016
Last Update Posted Date October 16, 2017
Study Start Date  ICMJE April 2009
Actual Primary Completion Date July 2013   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 6, 2017)
  • Successful Aneurysm Treatment [ Time Frame: 365 days ]
    defined as a composite endpoint of subjects who have successful delivery and deployment of the Anaconda™ Stent Graft at the initial procedure and at ≤365 days post-procedure and absence of:
    • Aneurysm growth ≥ 5 mm as evaluated by the core laboratory
    • Post-operative interventions to correct type I or III endoleaks
    • Conversion to open surgical repair
    • Failed patency of both limbs
    • Migration requiring secondary procedure or intervention
    • Significant fracture
    • Aneurysm rupture
  • Freedom From Major Adverse Events [ Time Frame: 30 days ]
    The reported values represent the patients that did not experience a Major Adverse Event. Participants did NOT experience:
    • All-Cause Mortality
    • Myocardial Infarction (MI)
    • Cerebrovascular Accident (CVA)
    • Renal Failure
    • Respiratory Failure
    • Paralysis or Paraplegia, or
    • Bowel Ischemia
Original Primary Outcome Measures  ICMJE Not Provided
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 6, 2017)
Secondary Effectiveness, Technical Success [ Time Frame: 24 hours ]
Introduction and deployment of the Stent Graft in the absence of mortality, conversion to surgical repair, failed patency of both limbs, and evidence of a Type I or III endoleak through the first 24 hour post-operative period. The table below indicates the subjects who met the criteria for technical success based on Core Lab imaging evaluations.
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE The Vascutek AnacondaTM Stent Graft System Phase II IDE Study
Official Title  ICMJE The Anaconda Endovascular Graft US FDA Phase II Clinical Study
Brief Summary The Phase I safety study is now complete. FDA approval has been granted to proceed to Phase II. The primary objectives of the Phase II study is to assess the safety and effectiveness of the Anaconda Stent Graft System in subjects presenting with abdominal aortic aneurysm (AAA). The secondary objectives of this study are to assess additional clinical outcomes measurements associated with treatment of AAA using the Anaconda Stent Graft System
Detailed Description Abdominal aortic aneurysms afflict a large number of patients in the United States and world-wide. The treatment of this disorder is based upon the concept of aneurysm repair prior to the presentation of symptoms or rupture. Thus aneurysm repair can be viewed as a prophylactic procedure embarked upon to prevent the disastrous complications of a ruptured aneurysm. The decision to treat an aneurysm electively is based upon a risk to benefit ratio. Treatment options include medical management of co-morbidities (hypertension, pulmonary disease, etc.) with observation of the aneurysm, open surgical aneurysm repair through a transabdominal or retroperitoneal approach, and endovascular aneurysm repair. The decision to intervene is based upon physician judgment. Once the decision to intervene is made, the mode of the intervention must be chosen. Although open surgical repair is more invasive and has been noted to have a higher morbidity and mortality(1;2) than most endovascular reports, few argue with the effectiveness of the procedure. To date, open surgical repair remains the gold standard of care for the aneurysm patient. Endovascular repair has several beneficial characteristics in comparison to an open surgical approach. They include the potential for decreased need for blood transfusions, shorter intensive care unit and total hospital stays, the lack of endotracheal intubation, to name a few. However, the procedure requires adequate imaging prior to graft placement and during the follow-up period, in addition to the availability of a trained team to ensure proper device placement.
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Infrarenal Abdominal Aortic Aneurysm
Intervention  ICMJE
  • Device: Anaconda Stent Graft System
    Endovascular device
  • Device: Anaconda ONE-LOK Stent Graft System
    Endovascular device
Study Arms  ICMJE Experimental: Anaconda
  • Device: Anaconda Stent Graft System
  • Device: Anaconda ONE-LOK Stent Graft System
Publications *

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: February 10, 2016)
Original Enrollment  ICMJE Not Provided
Actual Study Completion Date  ICMJE July 13, 2017
Actual Primary Completion Date July 2013   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male or female ≥18 and ≤ 85 years of age. Females must be non-pregnant, non-lactating, and not planning to become pregnant during the study period
  • Females of childbearing potential must use acceptable methods of contraception, be at least one year post-menopausal or be surgically sterile
  • Willing and able to comply with the 5 year follow-up period
  • Willing to give informed written consent prior to enrollment
  • Males with infrarenal AAA ≥ 4.5cm in diameter, or AAA growth ≥ 1.0cm/yr; females with infrarenal AAA ≥ 4.0cm in diameter, or AAA growth ≥ 1.0cm/yr
  • Infrarenal AAA with a proximal neck diameter of 16.0 - 31.0mm (Anaconda Stent Graft System)
  • Infrarenal AAA with a proximal neck diameter of 17.5 - 31.0mm (Anaconda ONE-LOK Stent Graft System)
  • Infrarenal AAA with at least 15mm length of non-aneurysm proximal neck
  • Infrarenal AAA with an angle of ≤ 60 degrees relative to the long axis of the aneurysm
  • Iliac artery distal fixation sites ≥ 20mm in length
  • Iliac artery distal fixation site ≤ 21mm in diameter
  • Ability to preserve at least one hypogastric artery
  • Femoral/iliac artery access vessels, size and morphology should be compatible with the appropriate introducer sheath (18 F, 20 F or 23 F).

Exclusion Criteria;

  • Pregnant and lactating females or females of childbearing potential unless using acceptable method contraception
  • Known sensitivity or allergy to nitinol or polyester
  • Known allergy or intolerance of radiopaque contrast agents which cannot be pre-treated
  • Thrombus, calcification, and/or plaque ≥ 2mm in thickness and/or ≥ 50% (180 degrees) continuous coverage of the vessel circumference in the intended fixation site
  • Irregularly shaped calcification and/or plaque that may compromise the sealing and fixation at the proximal or distal fixation sites
  • Ruptured or leaking AAA
  • Mycotic or inflammatory AAA
  • Genetic connective tissue disorder (i.e. Marfans or Ehlers-Danlos syndromes)
  • Previous AAA repair
  • Requires emergent AAA repair
  • Concomitant thoracoabdominal aortic aneurysm
  • Active systemic infection
  • Myocardial infarction ≤10 weeks prior to procedure
  • Aneurysm extends above renal arteries
  • Dialysis dependent renal failure or creatinine > 2.5mg/dL
  • Significant (>80%) renal artery stenosis not readily treatable
  • End-stage chronic obstructive pulmonary disorder
  • Patient is clinically and morbidly obese such that the required imaging would be prevented
  • Patient has an uncorrectable bleeding abnormality
  • Subject has other medical, social, or psychological problems that in the opinion of the investigator preclude them from receiving this treatment and the procedures and evaluations pre- and post- treatment
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 85 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   United States
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT00612924
Other Study ID Numbers  ICMJE ANA-006
G030036 ( Other Identifier: FDA G030036 )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Terumo CVS
Study Sponsor  ICMJE Terumo CVS
Collaborators  ICMJE Vascutek Ltd.
Investigators  ICMJE
Study Director: Steven Pregulman, MD Terumo Cardiovascular Systems Corporation
PRS Account Terumo CVS
Verification Date October 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP